HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase

References

• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005; 105: 2640–53
   PubMed Web of Science ®Google Scholar
• Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant. 2006; 12: 795–807
   PubMed Web of Science ®Google Scholar
• Passweg JR, Walker I, Scbocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukemia receiving allogeneic haematopoietic stem cell transplants. Br J Haematol. 2004; 125: 613–20
   PubMed Web of Science ®Google Scholar
• Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, Mcsweeney PA, et al. HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005; 11: 272–9
   PubMed Web of Science ®Google Scholar
• Carreras E, Jiménez M, Gómez-García V, de la Cámara R, Martín C, Martínez F, et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 2006; 37: 33–40
   PubMed Web of Science ®Google Scholar
• Benito AI, Diaz MA, Gonzalez-Vicent M, Sevilla J, Madero L. Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplant. 2004; 33: 675–90
   Google Scholar
• Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004; 32: 397–407
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, et al. Superior survival associated with transplantation of matched unrelated versus one-antigen disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood. 2002; 99: 806–14
   Google Scholar
• Speiser DE, Hermans J, Van Biezen A, Starobinski M, Jeannet M, Jacobsen N, et al. Haploidentical family member transplant for patients with chronic myeloid leukemia: a report of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997; 19: 1197–203
   Google Scholar
• Ottinger HD, Ferencik S, Beelen DW, Lindemann M, Peceny R, Elmaagacli AH, et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood. 2003; 102: 1131–7
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Felicini R, Carotti A, Falcinelli F, Tabilio A, et al. Haploidentical stem cell transplantation for acute leukemia. Int J Hematol 2002; 7(Suppl)165–8
   Google Scholar
• Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339: 1186–93
   PubMed Web of Science ®Google Scholar
• Van Rood JJ, Loberiz FR, Jr, Zhang MJ, Oudshoorn M, Claas F, Cairo MF, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002; 99: 1572–7
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong LJ, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006; 107: 3065–73
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological disease. Bone Marrow Transplant. 2006; 38: 291–7
   PubMed Web of Science ®Google Scholar
• Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica. 2004; 89: 1517–24
   PubMed Web of Science ®Google Scholar
• Liang X, Huang XJ. The differences between recombinant human granulocyte colony-stimulating factor-primed and non-primed peripheral blood stem cell harvests. Chin J Intern Med. 2007; 46: 566–8
   Google Scholar
• Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/habloidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007; 92: 414–7
   PubMedGoogle Scholar
• Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974; 18: 295–304
   PubMed Web of Science ®Google Scholar
• Huang XJ, Jiang Q, Chen H, Xu L, Liu D, Chen Y, et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005; 36: 343–8
   PubMed Web of Science ®Google Scholar
• Huang XJ, Chang YJ, Zhao XY. Maintaining hyporeponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transplant Immunol. 2007; 17: 193–7
   PubMed Web of Science ®Google Scholar
• Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002; 99: 4200–6
   PubMed Web of Science ®Google Scholar
• Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood. 2001; 98: 2922–9
   PubMed Web of Science ®Google Scholar
• Clift RA, Buckner CD, Thomas ED, Bryant E, Anasetti C, Bensinger WI, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994; 84: 4368–73
   Google Scholar
• International Bone Marrow Transplantation Registry. Available at: http://www.ibmtr.org.2002.
   Google Scholar
• Martin PJ, Clift RA, Fisher LD, Hansen JA, Appelbaum FR, Doney KC, et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood. 1988; 72: 1978–84
   PubMed Web of Science ®Google Scholar
• Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood. 2002; 99: 3861–2
   PubMed Web of Science ®Google Scholar
• Oehler VG, Gooley T, Synder DS, Johnston L, Lin A, Cummings CC, et al. The effects of imatinib mesylate treatment before allogeneic transplant for chronic myeloid leukemia. Blood. 2007; 109: 1782–9
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA. 2005; 102: 1992–7
   PubMed Web of Science ®Google Scholar